Drug
Icotrokinra clinical trials
Also written JNJ-77242113 and PN-21235,.
- studies test it
- 12
- open now
- 3
- in phase 3
- 6
- first study started
- 2021
Keep track of what changes. Save the icotrokinra studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Janssen Research & Development, LLC (10) · Janssen Pharmaceutical K.K. (2)
Studies
Open first, then newest update. How each study uses icotrokinra is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisRecruitingPhase 3Janssen Research & Development, LLCNCT06807424Written as Icotrokinra
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2/3Janssen Research & Development, LLCNCT07196722Written as Icotrokinra
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisRecruitingPhase 3Janssen Research & Development, LLCNCT07196748Written as Icotrokinra
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisActive, not recruitingPhase 3Janssen Pharmaceutical K.K.NCT06295692Written as JNJ-77242113
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06095115Written as JNJ-77242113
- A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06095102Written as JNJ-77242113
- A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05364554Written as JNJ-77242113
- A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05357755Written as JNJ-77242113
- A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Janssen Research & Development, LLCNCT06049017Written as JNJ-77242113
- A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05223868Written as JNJ-77242113
- A Study of JNJ-77242113 in Healthy Japanese and Chinese ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT05062200Written as JNJ-77242113
- A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05703841Written as JNJ-77242113
Given in every arm · 4 — icotrokinra is usual care beside what is tested
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06220604Written as JNJ-77242113
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06143878Written as JNJ-77242113
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06878404Written as Icotrokinra
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06934226Written as JNJ-77242113
Codes
What other systems call icotrokinra · ClinicalTrials.gg INT002191
- MeSH (NLM) C000732017icotrokinraOne source NLM
- UNII (FDA) MUW8FP7HNZICOTROKINRAConfirmed FDA, NLM, Wikidata
- Wikidata Q131418207icotrokinraConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C206920IcotrokinraOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732017 | icotrokinra | One source NLM |
| UNII (FDA) | MUW8FP7HNZ | ICOTROKINRA | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q131418207 | icotrokinra | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C206920 | Icotrokinra | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.